Divya C. Patel

Physician @UFmedicine passionate about taking care of and advocating for patients with #sarcoidosis and #ILD. Opinions presented are my own

[NEJM @NEJM]

Presented at #ATS2025:

In the PREDMETH trial, first-line treatment of pulmonary sarcoidosis with methotrexate was noninferior to that with prednisone regarding the change at 24 weeks in the percentage of the predicted forced vital capacity. Full trial results: https://t.co/a1fy9i358o

Editorial: Methotrexate as Initial Therapy for Symptomatic Pulmonary Sarcoidosis? https://t.co/PRMdtzkExy

@atscommunity

[American Thoracic Society (ATS) @atscommunity]

Check out Vivienne Kahlmann, MD, from the Erasmus Medical Center giving us a sneak peek of her paper, "Methotrexate Versus Prednisone as First-line Treatment for Pulmonary Sarcoidosis: The PREDMETH Trial", which she will be presenting at #ATS2025 Session A14, on May 18, Room 25, Hall E in the Moscone Center.

You can still register for ATS 2025! Register on-site or get the highlights package: https://t.co/M7cmvyA2eU

[ATS Clinical Problems Assembly @ATSCPAssembly]

#ATS2025 starts THIS WEEK! Prepare with our 🌟NEW PODCAST🌟 the CP Assembly's roadmap 🗺️ to #ATS2025! Join host Dr. Kerri Johannson as she breaks down must-see sessions at #ATS2025 with Drs. Kerri Aaronson, Justin Oldham, and @suryapbhatt https://t.co/PDJSTRWgzO

[EU-PFF @EU_IPFF]

Congratulations to @Boehringer with top line data on meeting the primary endpoint of the FIBRONEER phase III IPF-study. We are looking forward to learning more about effectiveness and safety data and are cheering on all activities that can provide patients with better treatment.

[Naftali Kaminski @KaminskiMed]

Wow! Boehringer-Ingelheim announces that Nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study - a decade after the first positive phase III trials for IPF. Cannot wait to see the full results but this EXCITING !!!
#CureIPF
https://t.co/TvI1P6uWpc

[Boehringer Ingelheim @Boehringer]

#NEWS: We’re excited to announce that our Phase III trial in people living with idiopathic pulmonary fibrosis (IPF) met its primary endpoint. 

Learn more here: https://t.co/KmlQf4lvyM

[Karen Moor @KarenMoor2]

Exciting results of the PREDMETH study #ERScongress. Methotrexate is as effective as Prednisone for pulmonary sarcoidosis after 24 weeks! @ILD_ErasmusMC @ers_ild @antoniuszkh

[Naftali Kaminski @KaminskiMed]

One more out from the #GRADS superteam!! "Chest CT provides more information than CXR in determining extent of physiologic impairment in pulmonary sarcoidosis" Kudos Drs Benn, Maier & GRADS investigators
#SaySarcoidosis #BeyondScadding #FundedByNHLBI
https://t.co/6f628Chs4b

[Deji Adegunsoye, MD, PhD @drdayjee]

Prof. Athol Wells presents elegant data from a recent multinational Delphi consensus that:

• Progression of ILD is progression irrespective of time since diagnosis

•“despite usual management” should be included in PPF definition

Important for future PPF guidelines.
#ATS2024

[CHEST @accpchest]

A Review of ACR/CHEST Clinical Practice Guidelines on Treatment of ILD With Systemic Autoimmune Rheumatic Diseases

Watch the full webinar by the Diffuse Lung Disease and Lung Transplant Network: https://t.co/Ggv4IpaTjc
#MedEd #MedTwitter #CHEST_ILDTx

[Deji Adegunsoye, MD, PhD @drdayjee]

Dr. Paul Wolters underscores the purpose of the diagnostic process. Identification of UIP is critical as it may be a singular unifier. However familial cases of PF may lack a UIP CT pattern. Telomere length is a common and very valuable biomarker that is helpful.

#ATS2024

[Divya C. Patel @DivyaCPatelDO]

@mwsharp5 Awesome turnout, Michelle! Thanks for organizing and helping the “family” stay connected. Any trainees looking for niche…think about #sarcoidosis. The nicest people work in sarcoidosis. #ATS2024

[James Diao @JamesADiao]

🧵 1/ What’s at stake with race-based equations for lung function? Clinical, occupational, and financial reclassifications for millions of patients.

I’m delighted to share this labor of love, published today in @NEJM and unveiled at #ATS2024.

https://t.co/9V0Bck071g

[Divya C. Patel @DivyaCPatelDO]

@GallodeMoraesMD @DGlaucomflecken @atscommunity 🤣

[Gisli Jenkins @IPFdoc]

https://t.co/8yYgeKnWvW

#ICLAF2024 program now available and it looks goooooood!

Excited to head to Athens in October and hear the latest advances in our understanding PF and our efforts to #CureIPF

[Divya C. Patel @DivyaCPatelDO]

@IPFdoc Getting the first opportunity to attend #ICLAF this year and can’t wait!

[Dr. Glaucomflecken @DGlaucomflecken]

Pulmonology AND critical care?? Idk seems like a lot

[Dr. Glaucomflecken @DGlaucomflecken]

I’m going to #ATS2024 tomorrow. I’m sitting here googling “do people say ARDSSS or A-R-D-S?” I’m too much of an ophthalmologist for this.

[Divya C. Patel @DivyaCPatelDO]

Excited join to address this impt issue #sarcoidosis @EnnisjamesM @YYandtd @obi_ogugua

Foundation for Sarcoidosis Research Launches the Coalition for Clinical Trial Equity to Address Barriers Faced by Black Patients https://t.co/hTyHQEVmIP

[ATS Clinical Problems Assembly @ATSCPAssembly]

The CP assembly will be announcing the mentoring, international member and early career achievement awards at the annual assembly meeting at #ATS2024.

Join us to find out the winners! 5pm PDT on Monday 5/20/24
🗺️ Marriott Marquis San Diego Pacific Ballroom 21-22 (Level One)